Loading…
Loading…
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
Comprehensive Money Management Services LLC decreased its position in shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM) by 74.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,241 shares of the company's stock after selling 15,264 shares
Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $40.19 and traded as high as $48.00. Global X Genomics and Biotechnology ETF shares last traded at $47.83, with a volume of 10,635
Shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $37.63 and traded as high as $45.62. Global X Genomics and Biotechnology ETF shares last traded at $45.13, with a volume of 17,129
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.